Health Utility Changes After Biologic Induction Therapy in Patients with Varying Severity of Psoriasis
Author(s)
Lu Jian, MD1, Guo Zhou, MD1, Xingzhi Wang, MD2, Kun Hu, MD1, Yongfang Duan, MD1, Mi Zhang, MD1, Liang Tan, MD3, Wendong Chen, MD, PhD4, Bingfa Li, MD1, Yehong Kuang, MD, PhD1;
1Xiangya Hospital of Central South University, Changsha, China, 2Bristol-Myers Squibb, Shanghai, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting Ltd, Mississauga, ON, Canada
1Xiangya Hospital of Central South University, Changsha, China, 2Bristol-Myers Squibb, Shanghai, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting Ltd, Mississauga, ON, Canada
Presentation Documents
OBJECTIVES: To support the customization of disease management goal from the perspective of quality of life, this study assessed health utility changes after biologic induction therapy for psoriasis in patients with different disease severity.
METHODS: Psoriasis patients with moderate or severe disease [based on Psoriasis Area and Severity Index (PASI) assessment prior to treatments] who received biologic induction therapy between January 2019 and May 2024 at a Chinese tertiary hospital were included. The documented PASI and the Dermatology Life Quality Index (DLQI) before and after induction therapy were collected for treatment response assessment and health utility estimation, using a mapping algorithm converting DLQI to the EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index. Health utility associated with PASI response was compared with the baseline utility prior to treatment in the patients with different disease severity, respectively. Multiple linear regression analyses were conducted to confirm the impact of PASI response on health utility.
RESULTS: 512 patients were analyzed (124 with moderate psoriasis and 388 with severe psoriasis). When compared to the baseline health utility prior to treatment, patients with PASI 75 or above could have significantly improved health utility, irrespective of their disease severity (moderate: PASI 75-89: 0.959 vs. 0.898, difference 0.061, p<0.001; PASI 90-99: 0.955 vs. 0.897, difference 0.058, p<0.001; PASI 100: 0.967 vs. 0.905, difference 0.062, p<0.001; severe: PASI 75-89: 0.938 vs. 0.846, difference 0.092, p<0.001; PASI 90-99: 0.944 vs. 0.837, difference 0.107, p<0.001; PASI 100: 0.964 vs. 0.832, difference 0.132, p<0.001). Multivariate linear regression analyses confirmed the significant improvement of health utility in patients with PASI 75 or above, irrespective of disease severity (moderate: coefficient 0.080 to 0.092, p<0.001; severe: coefficient 0.109 to 0.136, p<0.001).
CONCLUSIONS: Psoriasis patients achieving PASI 75 or above after biologic induction therapy could gain significant improvement of quality of life, irrespective of disease severity.
METHODS: Psoriasis patients with moderate or severe disease [based on Psoriasis Area and Severity Index (PASI) assessment prior to treatments] who received biologic induction therapy between January 2019 and May 2024 at a Chinese tertiary hospital were included. The documented PASI and the Dermatology Life Quality Index (DLQI) before and after induction therapy were collected for treatment response assessment and health utility estimation, using a mapping algorithm converting DLQI to the EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index. Health utility associated with PASI response was compared with the baseline utility prior to treatment in the patients with different disease severity, respectively. Multiple linear regression analyses were conducted to confirm the impact of PASI response on health utility.
RESULTS: 512 patients were analyzed (124 with moderate psoriasis and 388 with severe psoriasis). When compared to the baseline health utility prior to treatment, patients with PASI 75 or above could have significantly improved health utility, irrespective of their disease severity (moderate: PASI 75-89: 0.959 vs. 0.898, difference 0.061, p<0.001; PASI 90-99: 0.955 vs. 0.897, difference 0.058, p<0.001; PASI 100: 0.967 vs. 0.905, difference 0.062, p<0.001; severe: PASI 75-89: 0.938 vs. 0.846, difference 0.092, p<0.001; PASI 90-99: 0.944 vs. 0.837, difference 0.107, p<0.001; PASI 100: 0.964 vs. 0.832, difference 0.132, p<0.001). Multivariate linear regression analyses confirmed the significant improvement of health utility in patients with PASI 75 or above, irrespective of disease severity (moderate: coefficient 0.080 to 0.092, p<0.001; severe: coefficient 0.109 to 0.136, p<0.001).
CONCLUSIONS: Psoriasis patients achieving PASI 75 or above after biologic induction therapy could gain significant improvement of quality of life, irrespective of disease severity.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO201
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), STA: Biologics & Biosimilars